News

AbstractIntroductionTransthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease predominantly affecting older men and is associated with increasing care…

AbstractBackground Transthyretin amyloid cardiomyopathy (ATTR‐CM) is a rare, life‐threatening form of restrictive cardiomyopathy. Access to cardiology providers and…

AbstractBackgroundThe Mayo transthyretin amyloid cardiomyopathy (ATTR-CM) and AMY scores were developed to identify patients at risk for ATTR-CM. However, both were…

For women living with ATTR-Cardiac Amyloidosis (ATTR-CM), a serious heart disease that worsens over time, the path to diagnosis is rarely straightforward. Symptoms…

AbstractSystemic light chain (AL) amyloidosis is a rare, acquired protein misfolding disorder characterized by extracellular deposition of misfolded immunoglobulin…

AbstractBackgroundTransthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, often fatal disease caused by transthyretin (TTR) tetramer destabilization,…

Study OverviewBrief SummaryCardiac amyloidosis (CA) is an infiltrative disease characterized by deposits of amyloid proteins of genetic or acquired origin (often in…

This podcast by Dr. Ron Witteles reviews new data on transthyretin amyloid cardiomyopathy (ATTR‑CM), highlighting differences in transthyretin stabilization between…

People carrying the p.V142I mutation in the TTR gene — which is mostly associated with hereditary transthyretin amyloid cardiomyopathy (hATTR-CM) — often have…

Key Points Daratumumab monotherapy in stage IIIB AL amyloidosis showed rapid hematologic responses (75%; median time 1 week) and 65% 6-month survival.Treatment…